SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-330223
Filing Date
2017-11-02
Accepted
2017-11-02 07:03:03
Documents
7
Period of Report
2017-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d487980d8k.htm 8-K 46453
2 EX-2.1 d487980dex21.htm EX-2.1 587319
3 EX-3.1 d487980dex31.htm EX-3.1 4503
4 EX-99.1 d487980dex991.htm EX-99.1 67488
5 EX-99.2 d487980dex992.htm EX-99.2 44791
6 GRAPHIC g487980g1102093255215.jpg GRAPHIC 3043
7 GRAPHIC g487980g1102093255355.jpg GRAPHIC 4464
  Complete submission text file 0001193125-17-330223.txt   762585
Mailing Address 555 TWIN DOLPHIN DRIVE SUITE 615 REDWOOD CITY CA 94065
Business Address 555 TWIN DOLPHIN DRIVE SUITE 615 REDWOOD CITY CA 94065 6504750158
Ocera Therapeutics, Inc. (Filer) CIK: 0001274644 (see all company filings)

IRS No.: 631192270 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35119 | Film No.: 171170669
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1